Nelarabine in the treatment of refractory T-cell malignant diseases

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 13, 2006, Pages 1791-1799

  Kline, Justin ^a   Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute lymphoblastic leukaemia; Ara G; Lymphoblastic lymphoma; Nelarabine

Indexed keywords

ARABINONUCLEOSIDE; NELARABINE;

ANIMAL; CHEMISTRY; CLINICAL TRIAL; HUMAN; REVIEW; T CELL LEUKEMIA; TREATMENT OUTCOME;

ANIMALS; ARABINONUCLEOSIDES; CLINICAL TRIALS; HUMANS; LEUKEMIA, T-CELL; TREATMENT OUTCOME;

EID: 33947529458     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.13.1791     Document Type: Review

References (32)

1. REIST EJ, GOODMAN L: Synthesis of 9-β-D-arabinofuranosylguanine. Biochemistry (1964) 3:15-18.
2. KRENITSKY TA, KOSZALKA GW, TUTTLE JV et al.: An enzymatic synthesis of purine D-arabinonucleosides. Carbohydrate Res. (1981) 97:139-146.
3. LAMBE CU, AVERETT DR, PAFF MT et al.: 2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. (1995) 55:3352-3356.
4. RODRIGUEZ CO, GANDHI V: Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. (1999) 59:4937-4943. (Pubitemid 29472899)
5. SHEWACH DS, DADDONA PE, ASHCRAFT E: Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res. (1985) 45:1008-1014. (Pubitemid 15111252)
6. RODRIGUEZ CO, MITCHELL BS, AYRES M et al.: Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. (2002) 62:3100-3105. (Pubitemid 34602401)
7. PRUS KL, AVERETT DR, ZIMMERMAN TP: Transport and metabolism of 9-beta-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res. (1990) 50:1817-1821. (Pubitemid 20098827)
8. VERHOEF V, FRINLAND A: Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res. (1985) 45:3646-3650. (Pubitemid 15226439)
9. RODRIGUEZ CO, LEGHA JK, ESTEY E et al.: Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukaemia cells. Clin. Cancer Res. (1997) 3:2107-2113. (Pubitemid 27505139)
10. KRENITSKY TA, TUTTLE JV, KOSZALKA GW et al.: Deoxycytidine kinase from calf thymus. J. Biol. Chem. (1976) 251:4055-4061.
11. GANDHI V, PLUNKETT W: Modulatory activity of 2′, 2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. (1990) 50:3675-3680. (Pubitemid 20194115)
12. RODRIGUEZ CO, STELLRECHT CM, GANDHI V: Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood (2003) 102:1842-1848. (Pubitemid 37022581)
13. COHEN A, LEE JW, GELFAND EW: Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood (1983) 61:660-666.
14. GIBLETT ER, AMMANN AJ, WARA DW et al.: Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet (1975) 7914:1010-1013.
15. ULLMAN B, GUDAS LJ, CLIFT SM et al.: Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease. Proc. Natl. Acad. Sci. (1979) 76:1074-1078. (Pubitemid 9135156)
16. GANDHI V, PLUNKETT W, RODRIGUEZ CO et al.: Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J. Clin. Oncol. (1998) 16:3607-3615. (Pubitemid 28506775)
17. KISOR DF, PLUNKETT W, KURTZBERG J et al.: Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a Phase I study of nelarabine for the treatment of refractory hematologic malignancies. J. Clin. Oncol. (2000) 18:995-1003. •• An interesting and informative manuscript describing the pharmacokinetics of nelarabine in humans. (Pubitemid 30123775)
18. KURTZBERG J, ERNST TJ, KEATING MJ et al.: Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J. Clin. Oncol. (2005) 23:3396-3403. •• The initial Phase I trial to evaluate nelarabine in patients with relapsed/refractory haematological malignancies.
19. GANDHI V, PLUNKETT W, WELLER S et al.: Evaluation of the combination of nelarabine and fludaraine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemic cells. J. Clin. Oncol. (2001) 19:2142-2152. (Pubitemid 32366968)
20. KISOR DF: Nelarabine: a nucleoside analogue with efficacy in T-cell and other leukemias. Ann. Pharmacother. (2005) 39:1056-1062.
21. GANDHI V, PLUNKETT W: Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. (1988) 48:329-334. (Pubitemid 18045766)
22. BERG SL, BLANEY SM, DEVIDAS M et al.: Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the children's oncology group. J. Clin. Oncol. (2005) 23:3376-3382. •• Pivotal COG Phase II trial which evaluated the use of nelarabine in children and young adults with relapsed/refractory T cell malignancies.
23. DEANGELO D, YU D, DODGE RK et al.: A Phase II study of 2-amino-9-b-D arabinosyl-6-methoxy-9H purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): CALGB study 19801. Blood (2002) 100(S1): Abstract 198a. •• Pivotal CALGB Phase II study of nelarabine in adults with relapsed/refractory T-ALL/LBL.
24. GOEKBUGET N, ARNOLD R, ATTA J et al.: Compound GW506U78 has high single-drug activity and good feasibility in heavily pretreated relapsed T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) and offers the option for cure with stem cell transplantation (SCT). Blood (2005) 106(S1) Abstract 150. •• GMALL Phase II study of nelarabine in adults with relapsed/refractory T-ALL/LBL.
25. CZUCZMAN MS, PIERLUIGI P, JOHNSON J et al.: Results of a Phase II study of 506U78 in CTCL and PTCL. Blood (2004) 104(S1) Abstract 2486.
26. THOMPSON MA, PRO B, SARRIS A et al.: Results of a Phase II study of 506U78 (Nelarabine) in refractory indolent B-cell or peripheral T-cell lymphoma. Blood (2005) 106(S1) Abstract 2681.
27. O'BRIEN S, THOMAS D, KANTARJIAN H et al.: Compound 506 has activity in mature lymphoid leukemia. Blood (1998) 92(S1) Abstract 2022.
28. PUI CH, EVANS WE: Treatment of acute lymphoblastic leukemia. New Engl. J. Med. (2006) 354:166-178. (Pubitemid 43076714)
29. LARSON RA, DODGE RK, BURNS P et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood (1995) 85:2025-2037.
30. GOEKBUGET N, ARNOLD R, BUECHNER T et al.: Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in the GMALL study 05/93. Blood (2001) 98(S1) Abstract 3338. (Pubitemid 33790597)
31. KLINE JP, LARSON RA: Clofarabine in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia: a review. Expert Opin. Pharmacother. (2005) 6:2711-2718. (Pubitemid 41824385)
32. WENG AP, FERRANDO AA, LEE W et al.: Activating mutations in NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 306:269-271. (Pubitemid 39336870)